Free Trial

Sanofi (SNY) Stock Price, News & Analysis

Sanofi logo
$54.62 +0.67 (+1.24%)
Closing price 04/3/2025 04:00 PM Eastern
Extended Trading
$53.93 -0.69 (-1.27%)
As of 04:17 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Sanofi Stock (NASDAQ:SNY)

Key Stats

Today's Range
$54.58
$55.77
50-Day Range
$52.37
$59.42
52-Week Range
$45.22
$60.12
Volume
1.84 million shs
Average Volume
2.27 million shs
Market Capitalization
$138.62 billion
P/E Ratio
21.94
Dividend Yield
2.69%
Price Target
$62.50
Consensus Rating
Buy

Company Overview

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Remove Ads

Sanofi Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
66th Percentile Overall Score

SNY MarketRank™: 

Sanofi scored higher than 66% of companies evaluated by MarketBeat, and ranked 317th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Sanofi has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Sanofi has only been the subject of 3 research reports in the past 90 days.

  • Read more about Sanofi's stock forecast and price target.
  • Earnings Growth

    Earnings for Sanofi are expected to grow by 8.94% in the coming year, from $4.36 to $4.75 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Sanofi is 21.94, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 21.93.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Sanofi is 21.94, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 23.24.

  • Price to Earnings Growth Ratio

    Sanofi has a PEG Ratio of 1.01. PEG Ratios around 1 indicate that a company is correctly valued.

  • Price to Book Value per Share Ratio

    Sanofi has a P/B Ratio of 1.65. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Sanofi's valuation and earnings.
  • Percentage of Shares Shorted

    0.23% of the float of Sanofi has been sold short.
  • Short Interest Ratio / Days to Cover

    Sanofi has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Sanofi has recently increased by 3.51%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Sanofi pays a meaningful dividend of 2.69%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Sanofi does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Sanofi is 59.04%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Sanofi will have a dividend payout ratio of 30.95% next year. This indicates that Sanofi will be able to sustain or increase its dividend.

  • Read more about Sanofi's dividend.
  • Percentage of Shares Shorted

    0.23% of the float of Sanofi has been sold short.
  • Short Interest Ratio / Days to Cover

    Sanofi has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Sanofi has recently increased by 3.51%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Sanofi has a news sentiment score of 1.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 27 news articles for Sanofi this week, compared to 14 articles on an average week.
  • Search Interest

    7 people have searched for SNY on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.
  • MarketBeat Follows

    11 people have added Sanofi to their MarketBeat watchlist in the last 30 days. This is an increase of 267% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Sanofi insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.00% of the stock of Sanofi is held by insiders.

  • Percentage Held by Institutions

    Only 14.04% of the stock of Sanofi is held by institutions.

  • Read more about Sanofi's insider trading history.
Receive SNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sanofi and its competitors with MarketBeat's FREE daily newsletter.

SNY Stock News Headlines

EU’s Action Takes Aim At US Retirees
Trump's Return Sparks Massive Gold Rush—Is Your 401(k) Ready for the Fallout? With President Trump back and global powers like China, Russia, and even Europe rapidly moving away from the U.S. dollar, central banks and financial giants are frantically buying gold at historic rates. This massive shift threatens your retirement savings with inflation and market instability—potentially worse than 2008. But you can protect yourself today by leveraging a little-known IRS loophole that lets you diversify your IRA or 401(k) into gold—tax-free and penalty-free.
Is Sanofi (SNY)the Best Gene-Editing Stock to Buy?
Sanofi treatment of immunoglobulin G4-related disease granted orphan status
See More Headlines

SNY Stock Analysis - Frequently Asked Questions

Sanofi's stock was trading at $48.23 at the start of the year. Since then, SNY stock has increased by 13.2% and is now trading at $54.62.
View the best growth stocks for 2025 here
.

Sanofi (NASDAQ:SNY) released its quarterly earnings results on Thursday, January, 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.70. Sanofi had a trailing twelve-month return on equity of 25.61% and a net margin of 12.77%.

The following companies are subsidiaries of Sanofi: Kiadis Pharma, Principia BioPharma, Synthorx, Ablynx, Bioverativ, Aventis S.A., Ablynx N.V., and more.

Sanofi's top institutional investors include First Hawaiian Bank, Central Pacific Bank Trust Division, Versant Capital Management Inc and Marcum Wealth LLC.
View institutional ownership trends
.

Shares of SNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Sanofi investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR).

Company Calendar

Last Earnings
1/30/2025
Today
4/03/2025
Next Earnings (Estimated)
4/24/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SNY
Employees
91,600
Year Founded
2004

Price Target and Rating

Average Stock Price Target
$62.50
High Stock Price Target
$65.00
Low Stock Price Target
$60.00
Potential Upside/Downside
+14.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
21.94
Forward P/E Ratio
12.53
P/E Growth
1.01
Net Income
$6.02 billion
Pretax Margin
15.12%

Debt

Sales & Book Value

Annual Sales
$44.29 billion
Cash Flow
$5.38 per share
Price / Cash Flow
10.16
Book Value
$33.20 per share
Price / Book
1.65

Miscellaneous

Outstanding Shares
2,537,845,000
Free Float
2,512,467,000
Market Cap
$138.62 billion
Optionable
Optionable
Beta
0.58

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:SNY) was last updated on 4/4/2025 by MarketBeat.com Staff
From Our Partners